Earlier today the MAPRx Coalition released the Issue Brief: Minimizing Affordability Challenges and Beneficiary Confusion. Linked HERE. Highlights of the Issue Brief: Key finalized provisions from Part 1 Guidance Key proposed provisions from Part 2 Guidance Key insights from coalition…
Earlier today, the MAPRx Coalition submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the implementation of the Medicare Prescription Payment Plan program set to take effect for Contract Year (CY) 2025 per the Memorandum Maximum Monthly…
Earlier today, the MAPRx Coalition submitted to the Centers for Medicare & Medicaid Services (CMS) comments regarding the implementation of the Medicare Drug Price Negotiation Program (MDPNP) for initial price applicability year 2026. The Coalition appreciates the opportunity to comment…
A new report commissioned by the MAPRx Coalition examines the growing clinical evidence for coverage of anti-obesity medications (AOMs) approved by the Food and Drug Administration in Medicare Part D. As the medical community’s understanding of disease states evolves, MAPRx…
Earlier today, the MAPRx Coalition and 35 member organizations submitted a letter to Senate leadership ahead of their continued consideration of the Inflation Reduction Act of 2022 via the Senate’s reconciliation process. While members of the Coalition have differing views…
Earlier today, 29 members of the MAPRx Coalition sent a letter to Congressional leaders urging them to establish an out-of-pocket (OOP) cap for Medicare Part D to limit the amount Medicare beneficiaries have to pay for covered prescription drugs. The…
Earlier today, the MAPRx Coalition hosted a virtual briefing for members of Congress, their staff, and MAPRx member organizations. After Corey Ford of Xcenda provided an overview of the Medicare Part D benefit, Illy Jaffer of the American Cancer Society…
Earlier today, the MAPRx Coalition and 27 of its member organizations submitted letters to House and Senate leadership in response to the ongoing congressional efforts to address drug pricing and affordability. Specifically, the letters urged congressional leaders to focus on…